Search results for "transplant recipient"

showing 10 items of 49 documents

Anti-HLA alloantibodies of the IgA isotype in re-transplant candidates part II: Correlation with graft survival

2017

We reported previously on the widespread occurrence of anti-HLA alloantibodies of the IgA isotype (anti-HLA IgA) in the sera of solid-organ re-transplantation (re-tx) candidates (Arnold et al., ). Specifically focussing on kidney re-tx patients, we now extended our earlier findings by examining the impact of the presence and donor specificity of anti-HLA IgA on graft survival. We observed frequent concurrence of anti-HLA IgA and anti-HLA IgG in 27% of our multicenter collective of 694 kidney re-tx patients. This subgroup displayed significantly reduced graft survival as evidenced by the median time to first dialysis after transplantation (TTD 77 months) compared to patients carrying either …

Male0301 basic medicinemedicine.medical_treatmentMedizinHistocompatibility Testing030230 surgery0302 clinical medicineAntibody SpecificityHLA AntigensIsoantibodiesMedicineChildGenetics (clinical)Aged 80 and overKidneybiologyGraft SurvivalGeneral MedicineMiddle AgedPrognosisIsotypemedicine.anatomical_structureChild PreschoolRetreatmentFemaleAntibodyAdultAdolescentImmunologyHuman leukocyte antigenYoung Adult03 medical and health sciencesGeneticsHumansMolecular BiologyAllelesDialysisAgedbusiness.industryOrgan TransplantationKidney TransplantationTransplant RecipientsImmunoglobulin ATransplantation030104 developmental biologyImmunoglobulin GImmunologybiology.proteinGraft survivalbusinessInternational Journal of Immunogenetics
researchProduct

Occult hepatitis B virus infection

2000

Many studies have shown that hepatitis B virus infection may also occur in hepatitis B surface antigen-negative patients. This occult infection has been identified both in patients with cryptogenic liver disease and in patients with hepatitis C virus-related chronic hepatitis, and much evidence suggests that it may be a risk factor of hepatocellular carcinoma development. However several aspects of this occult infection remain unclear such as its prevalence and the factor(s) involved in the lack of circulating hepatitis B surface antigen. Moreover, it is uncertain whether the occult hepatitis B virus infection may contribute to chronic liver damage, considering that it is usually associated…

MaleACUTE VIRAL-HEPATITISPOSTTRANSFUSION HEPATITISHBV SURFACE-ANTIGENComorbidityHBV genome HBsAg-negative liver DNA liver diseasemedicine.disease_causeSeverity of Illness IndexSEROLOGICAL MARKERS; TRANSPLANT RECIPIENTS; POSTTRANSFUSION HEPATITIS; HEPATITIS C VIRUS; HEPATOCELLULAR-CARCINOMA; HBV SURFACE-ANTIGEN; ACUTE VIRAL-HEPATITIS; CHRONIC LIVER-DISEASE; POLYMERASE CHAIN-REACTION; occult hepatitis B virus infectionLiver diseaseCHRONIC LIVER-DISEASEHEPATOCELLULAR-CARCINOMAChronic/diagnosis* Hepatitis BDifferential Disease Progression Female Hepatitis B Surface Antigens/analysis* Hepatitis Bhbsag-negative; hbv genome; liver disease; liver dnaIncidenceHepatocellular/diagnosis CarcinomaLiver NeoplasmsGastroenterologyHepatitis CHepatitis BPOLYMERASE CHAIN-REACTIONPrognosisChronic/epidemiology* Humans Incidence Liver Neoplasms/diagnosis Liver Neoplasms/epidemiology* Male Prognosis Risk Assessment Severity of Illness IndexCarcinoma Hepatocellular/diagnosis Carcinoma Hepatocellular/epidemiology* Comorbidity DNA Viral/analysis Diagnosis Differential Disease Progression Female Hepatitis B Surface Antigens/analysis* Hepatitis B Chronic/diagnosis* Hepatitis B Chronic/epidemiology* Humans Incidence Liver Neoplasms/diagnosis Liver Neoplasms/epidemiology* Male Prognosis Risk Assessment Severity of Illness IndexHepatocellular carcinomaDisease Progressionhbv genomeFemaleliver diseaseCarcinoma HepatocellularTRANSPLANT RECIPIENTSRisk AssessmentDiagnosis Differentialoccult hepatitis B virus infectionHepatitis B ChronicViral/analysis DiagnosismedicineHumansRisk factorHepatitis B virusHepatitis B Surface AntigensHepatologybusiness.industryCarcinomaHEPATITIS C VIRUShbsag-negativeliver dnamedicine.diseaseOccultVirologyHepatocellular/epidemiology* Comorbidity DNASEROLOGICAL MARKERSViral replicationImmunologyDNA Viralbusiness
researchProduct

Sirolimus exposure and the occurrence of cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation

2018

Sirolimus appears to protect against cytomegalovirus (CMV) in organ transplant recipients. The effect of this drug in allogeneic hematopoietic stem cell transplantation recipients remains unexplored. By means of multivariate continuous-time Markov model analyses, we identified 3 independent covariates that significantly impacted the risk of CMV DNAemia: recipient/donor CMV serostatus, tacrolimus exposure, and sirolimus exposure. CMV-seropositive recipients with CMV-seronegative donors had a significantly higher probability of having detectable CMV DNAemia. Increasing the tacrolimus trough concentration from 0 to 16 ng/mL increased the probability of patients having detectable CMV DNAemia by…

Malebasic (laboratory) research/science0301 basic medicinemedicine.medical_treatmentCytomegalovirusHematopoietic stem cell transplantationGastroenterologyOrgan transplantation0302 clinical medicineRisk FactorsImmunology and AllergyPharmacology (medical)Whole bloodIncidenceHematopoietic Stem Cell Transplantationvirus diseasesMiddle AgedPrognosissurgical procedures operativeCytomegalovirus Infectionscytomegalovirus (CMV) [infection and infectious agents-viral]Femaleantiviral [antibiotic]pharmacokinetics/pharmacodynamicsImmunosuppressive Agentsmedicine.drugAdultmedicine.medical_specialtyinfectious diseasesirolimus [immunosuppressant-mechanistic target of rapamycin]clinical research/practicetacrolimus [immunosuppressant-calcineurin inhibitor]03 medical and health sciencesInternal medicinemedicineHumansTransplantation HomologousTrough ConcentrationViremiabone marrow/hematopoietic stem cell transplantationAgedSirolimusTransplantationbusiness.industryTransplant RecipientsTacrolimus030104 developmental biologySpainRelative riskSirolimusDNA ViralpharmacologybusinessSerostatusFollow-Up Studies030215 immunology
researchProduct

CAR-T therapy in solid transplant recipients with post-transplant lymphoproliferative disease: case report and literature review

2021

Patients with postransplant lymphoproliferative disease (PTLD) who are refractory to rituximab-based regimens have extremely poor prognosis. Data is lacking in the setting of solid organ transplantation (SOT)-related PTLD treated with chimeric antigen receptor T-cell (CAR-T) therapy. Moreover, limited information is available on the influence of concomitant immunosuppressive drugs on CAR-T function. Here, we describe the clinical outcome in one PTLD patient and propose a strategy for tailoring immunosuppressive treatment and organ monitoring in patients with kidney allografts after CAR-T infusion. This report also reviews the limited published data in the setting of SOT-related PTLD treated…

Oncologymedicine.medical_specialtymedicine.medical_treatmentImmunotherapy AdoptiveGeneral Biochemistry Genetics and Molecular BiologyRefractoryhemic and lymphatic diseasesInternal medicinemedicineHumansKidneyReceptors Chimeric Antigenbusiness.industryImmunosuppressionOrgan TransplantationGeneral MedicineLymphoproliferative DisordersTransplant RecipientsChimeric antigen receptorDiscontinuationsurgical procedures operativemedicine.anatomical_structureConcomitantRituximabLymphoproliferative diseasebusinessmedicine.drugCurrent Research in Translational Medicine
researchProduct

Ex-vivo generation and in-vivo infusion of Herpesvirus-specific T cells to treat virus-induced pathologies in transplant recipients.

2011

Settore MED/04 - Patologia Generalevirus-induced pathologietransplant recipients.Herpesvirus-specific T cellex-vivo generation and in-vivo infusion
researchProduct

Single center report on complications in steroid-free immunosuppressive therapy of liver transplant recipients

2010

Steroid-Free Immunosuppressive Therapy Liver Transplant Recipients
researchProduct

Human genetic polymorphisms and risk of viral infection after solid organ transplantation.

2021

The immune system plays a key role in the host defense against viral pathogens. A signaling cascade is activated upon infection involving a variety of molecules such as pattern-recognition receptors (PRRs), interleukins or antiviral interferons. Long-term immunosuppression after solid organ transplantation (SOT) mainly abrogates adaptive T-cell-mediated responses, thus highlighting the relative contribution of innate immunity. Single-nucleotide polymorphisms (SNPs) within genes coding for PRRs or soluble mediators have been associated with differential susceptibility to viral infections among SOT recipients. A protective effect against cytomegalovirus (CMV) infection or disease has been att…

TransplantationInnate immune systembusiness.industryvirusesmedicine.medical_treatmentVaricella zoster virusImmunosuppressionHerpes SimplexDiseaseOrgan Transplantationmedicine.disease_causeAntiviral AgentsMannose-Binding LectinPolymorphism Single NucleotideTransplant RecipientsTLR2Immune systemImmunologyCytomegalovirus InfectionsGenetic predispositionmedicineHumansHuman viromebusinessImmunosuppressive AgentsTransplantation reviews (Orlando, Fla.)
researchProduct

Kardiovaskulārā riska izvērtējums pacientiem ar nieres transplantātu

2022

Viens no biežākajiem nāves iemesliem pacientiem ar funkcionējošu nieres transplantātu ir kardiovaskulāri (KV) notikumi. Lai savlaicīgi varētu veikt preventīvu ārstēšanu un uzlabot nieres transplantāta recipientu dzīvildzi, ir nozīmīgi izvērtēt svarīgākos KV riska faktorus un to ietekmi uz KV notikumu attīstību. Retrospektīva pētījuma mērķis bija izvērtēt KV notikumu incidenci, riska faktorus un nieres transplantācijas (NT) iznākumus pacientiem ar KV notikumiem. Pētījumā tika iekļauti 184 pacienti. Datu analīzei pacienti tika sadalīti divās grupās: pacienti ar KV notikumiem un pacienti bez KV notikumiem. Glomerulārās filtrācijas ātrums tika aprēķināts pēc CKD-EPI Creatinine, 2021 formulas. R…

cardiovascular risknieres transplantāta funkcijanieres transplantāta recipientikidney transplant recipientsMedicīnakardiovaskulārais risks
researchProduct

A challenging case of chorioretinitis and skin lesions in a lung transplant recipient

2018

no

infection and infectious agentsmedicine.medical_specialtyinfectious diseaseclinical research/practicecomplication: infectioulung transplantation/pulmonologyBiopsymedicineImmunology and AllergybiopsyPharmacology (medical)Lung transplant recipientTransplantationmedicine.diagnostic_testinfection and infectious agentbusiness.industryChorioretinitisantibiotic: antifungalmedicine.diseaseinfection and infectious agents - fungalDermatologycomplication: infectiousAntibiotics antifungalInfectious disease (medical specialty)Skin lesionbusinessantibiotic: antifungal; biopsy; clinical research/practice; complication: infectious; infection and infectious agents; infection and infectious agents - fungal; infectious disease; lung transplantation/pulmonology; Immunology and Allergy; Transplantation; Pharmacology (medical)American Journal of Transplantation
researchProduct

Italian association for the study of the liver position statement on SARS-CoV2 vaccination.

2021

The vaccination campaign against Sars-CoV-2 commenced in Italy at the end of December 2020. The first ones to receive the immunization against the virus were the health workers and the residents of nursing homes, following which the vaccine would be available for the entire population, beginning with the most vulnerable individuals. SARS-CoV2 vaccines have been demonstrated to be safe for the general population, although no data for patients with liver diseases or those having undergone liver transplantation are available so far. The present position statement AISF is an attempt to suggest, based on the published data on the impact of Sars-Cov-2 infection in patients with chronic liver dise…

medicine.medical_specialtyCOVID-19 VaccinesSars-CoV-2medicine.medical_treatmentPopulationLiver transplantationChronic liver diseaseRisk AssessmentPatient safetyEpidemiologyMedicineChronic liver disease Sars-CoV-2 Vaccination Humans Immunosuppressive Agents Italy Liver Transplantation Patient Safety Patient Selection Risk Adjustment Risk Assessment SARS-CoV-2 Transplant Recipients Treatment Outcome COVID-19 COVID-19 Vaccines Immunization Programs Liver DiseasesHumanseducationeducation.field_of_studyHepatologybusiness.industryImmunization ProgramsLiver DiseasesPatient SelectionChronic liver disease; Sars-CoV-2; VaccinationVaccinationChronic liver diseaseGastroenterologyCOVID-19medicine.diseaseTransplant RecipientsLiver TransplantationVaccinationTreatment OutcomeImmunizationItalyFamily medicineChronic liver disease; Sars-CoV-2; Vaccination; Humans; Immunosuppressive Agents; Italy; Liver Transplantation; Patient Safety; Patient Selection; Risk Adjustment; Risk Assessment; SARS-CoV-2; Transplant Recipients; Treatment Outcome; COVID-19; COVID-19 Vaccines; Immunization Programs; Liver DiseasesRisk AdjustmentPatient SafetyPosition PaperbusinessRisk assessmentImmunosuppressive AgentsDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct